Search company, investor...

Asthmatx

asthmatx.com

Founded Year

2003

Stage

Acquired | Acquired

Total Raised

$42.5M

Valuation

$0000 

About Asthmatx

Asthmatx has developed and patented a radiofrequency catheter and controller for reducing the amount of airway smooth muscle tissue in the lungs of asthma patients. This procedure aims to improve the pulmonary function of moderate and severe asthmatics.

Headquarters Location

1340 Space Park Way

Mountain View, California, 94043,

United States

650-810-1100

Missing: Asthmatx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Asthmatx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Asthmatx Patents

Asthmatx has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/22/2014

6/15/2021

Respiratory therapy, Lung disorders, Respiratory diseases, Respiratory physiology, Muscarinic antagonists

Grant

Application Date

12/22/2014

Grant Date

6/15/2021

Title

Related Topics

Respiratory therapy, Lung disorders, Respiratory diseases, Respiratory physiology, Muscarinic antagonists

Status

Grant

Latest Asthmatx News

Morgan Stanley Upgrades Boston Scientific on Pipeline Acceleration

Jan 6, 2014

Facebook, Boeing, PayPal PTs Hiked; Twitter Downgraded (Investor's Business Daily) In a report published Monday, Morgan Stanley analyst David Lewis upgraded Boston Scientific (NYSE: BSX ) from Equal-weight to Overweight based on pipeline acceleration traction. Despite disappointing pipeline progress in 2013 from Asthmatx reimbursement delays and S-ICD manufacturing constraints, Morgan Stanley expects sales results to improve. Morgan Stanley's updated model shows risk-adjusted pipeline sales of $90 million (130 bps) in 2014 and $145 million (180 bps) in 2015, which drives a $0.07 (8%) EPS accretion by 2015. Lewis reported that Boston Scientific has the best opportunity for margin improvements in cardiology. The analyst commented, “At 19%, cash operating margins are depressed relative to peers. In particular, CRM margins of 12-13% are half those of competitors; normalizing CRM profitability alone could drive 15%+ upside to EPS over several years. Structural cost programs have done an impressive job of supporting the P&L during a multi-year contraction in revenue, but margin results should accelerate in a more visible way as revenue growth rates push into the mid single digits and drive much better leverage over a fully-loaded expense structure.” Shares of Boston Scientific Corporation closed at $11.93 on Friday and is currently trading at $12.28, up 2.93%. Latest Ratings for BSX

Asthmatx Frequently Asked Questions (FAQ)

  • When was Asthmatx founded?

    Asthmatx was founded in 2003.

  • Where is Asthmatx's headquarters?

    Asthmatx's headquarters is located at 1340 Space Park Way, Mountain View.

  • What is Asthmatx's latest funding round?

    Asthmatx's latest funding round is Acquired.

  • How much did Asthmatx raise?

    Asthmatx raised a total of $42.5M.

  • Who are the investors of Asthmatx?

    Investors of Asthmatx include Boston Scientific, MedVenture Associates, Montreux Equity Partners, Menlo Ventures, General Mills and 18 more.

  • Who are Asthmatx's competitors?

    Competitors of Asthmatx include Broncus Medical, EndoGastric Solutions, CSA Medical, Solace Therapeutics, Uptake Medical and 11 more.

Compare Asthmatx to Competitors

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

C
Continence Control Systems International

CCS is developing a device to aid colostomy patients in managing their stomas (formerly Uniseed investee Colocare) and a surgical procedure for urinary incontinence based on electrical stimulation of smooth muscle grafts. Both technologies are currently under clinical evaluation.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

U
Urovalve

Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.

OrthAlign Logo
OrthAlign

OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.

N
NuOrtho Surgical

NuOrtho Surgical is a medical device company which is developing a probe that uses low-level radio frequencies to smooth and contour frayed or torn knee cartilage.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.